secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001730463-25-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission
--------------------------------------------------------------------------------

- Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
- Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.
- FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.
- Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.
- Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/0001730463-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autl-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001730463-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer